Keywords

• Brimonidine Tartrate
• Brimonidine Tartrate powder
• 99% Brimonidine Tartrate

Quick Details

• ProName: cas 70359-46-5 99% Brimonidine Tartr...
• CasNo: 70359-46-5
• Molecular Formula: C15H22O5
• Appearance: white
• Application: Brimonidine is a highly selective α2-r...
• DeliveryTime: 7-10 days
• PackAge: drum
• Port: Shanghai/Wuhan
• ProductionCapacity: 1000 Kilogram/Month
• Purity: 99
• Storage: room
• LimitNum: 1 Kilogram

Superiority

cas  70359-46-5 99%  Brimonidine Tartrate powder 

Product Name:    Brimonidine Tartrate
CAS:    70359-46-5
MF:    C15H16BrN5O6
MW:    442.22
EINECS:    629-848-5

Details

cas  70359-46-5 99%  Brimonidine Tartrate powder 

Product Name:    Brimonidine Tartrate
CAS:    70359-46-5
MF:    C15H16BrN5O6
MW:    442.22
EINECS:    629-848-5

Brimonidine is a highly selective α2-receptor blocker, successfully, which is an eye medication. It can reduce intraocular pressure (IOP). Brimonidine tartrate ophthalmic solution saling in the market is brimonidine tartrate form, which is a good IOP-lowering medication for chronic open-angle glaucoma and ocular hypertension treatment of patients, but also for argon laser IOP levels.

Brimonidine tartrate ophthalmic solution has a dual mechanism of action by reducing aqueous humor production and increasing the pigment layer of liquid scleral outflow therapeutic purposes. After dropping into the eye, the effect is rapid, and it can reach the peak when using up to 2h, and the effective time can maintain 12h. Blood can only detect traces of drugs. This product has first-pass metabolism in the liver, and metabolites excreted in the urine by the kidneys. Systemic absorption and distribution are not affected, and the elderly do not need dose adjustment.
 Brimonidine tartrate ophthalmic solution compared with other α-blockers, the fat-soluble is small, while it does not easy to pass through blood-brain barrier and does not produce sedation, hypotension and other similar clonidine central adverse reactions.
Brimonidine tartrate ophthalmic solution is highly selective for α2-adrenergic receptors, and α2/α1 ratio of receptor affinity is more than 1000 times. The effect of alpha 2 receptors can lead to lower intraocular pressure. And the role of the alpha 1 receptors can lead to vascular contraction, eyelid retraction or reduction and dilation of the pupil. Long term application of this product will not cause rapid desensitization.
In addition, compared with β-blockers, brimonidine tartrate eye drops for minor cardiovascular effects, it has no effect on lung function, so it is suitable for disabled patients β-blockers.